New drug candidate AH-008 takes first step toward easing chemotherapy nerve pain

NCT ID NCT07697560

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This early-stage trial tests the safety and tolerability of a single dose of AH-008, a potential treatment for chemotherapy-induced peripheral neuropathy (nerve damage). Healthy adults aged 18 to 65 receive either AH-008 or a placebo by intravenous infusion. The study monitors side effects and how the drug moves through the body, laying the groundwork for future patient trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AH-008
What this could lead to
If safe and well-tolerated, AH-008 could be tested in patients with chemotherapy-induced peripheral neuropathy, potentially leading to a new treatment for this painful condition.
What could go wrong
This is an early, first-in-human study with only 32 healthy participants. It is designed to check safety, not effectiveness, and many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICON Clinial Research Unit

    RECRUITING

    Salt Lake City, Utah, 84124, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.